openPR Logo
Press release

The Biobetters Market to stumble upon digital transformation from 2019-2029, reaching US$ 99,000.0 Mn

05-23-2022 01:11 PM CET | Health & Medicine

Press release from: Persistence Market Research

The Biobetters Market to stumble upon digital transformation

The Biobetters Market is meant to grow remarkably in the upcoming decade. NLP is the new "normalized" normal. NLP does deal with various interactions between human languages and computers. In other words, combining deep learning and analytical tools lets interpretation of medical data and improvement in the clinical decision for driving NLP's growth in healthcare.

Increasing usage of therapeutically more effective drugs for the treatment of chronic diseases is expected to drive the growth of biobetters market. Higher efficacy and lower adverse effects are among the important factors that are expected to fuel the growth of the biobetters market over the forecast period.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/21151

According to the latest research by the company, the global biobetters market is projected to account for a market value of around US$ 99,000.0 Mn by the end of 2029. The report also projects a significant growth potential for the biobetters market throughout the forecast period.

Company Profiles:

F.Hoffmann-La Roche AG
Merck & Co. Inc.
Sanofi SA
SERVIER
Porton Biopharma Limited
Eli Lily and Company
Novo Nordisk A/S
Biogen Inc.
CSL Behring GmbH
Teva Pharmaceutical Industries Ltd.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/21151

Better Therapeutic Outcome at Lower Costs

Lower cost of treating various chronic diseases with the usage of biobetters is one of the prominent factors contributing to the substantial growth of the biobetters market. Biobetters are more effective and longer-acting medicines as compared to biosimilars, which are their reference biologic products. Although biosimilars are 20 to 30% cheaper as compared to biobetters, superior efficacy and lesser dosage frequency makes biobetters a preferred treatment option.

Moreover, the treatment cost of each cycle using biobetters is relatively lower than that of biologics. For example, Neulasta, a biobetter of Neupogen, costs around US$ 3,400 - 4,000 for each treatment cycle, whereas Neupogen cost around US$ 6,000 at the inception. Although the cost of Neulasta increased considerably, it made only a little difference due to its increased patient compliance and efficacy.

However, the market share of Neupogen and its biosimilars remains significantly low, when compared to Neulasta. The superiority of biobetters in terms of pricing, dosage, efficacy, etc. makes them among the most preferred treatment options among patients as well as healthcare professionals.

Various pharmaceutical and biopharmaceutical companies are seeking approval for their respective biobetters for the treatment various diseases. For example, on May 7, 2019, Roche received approval for its Kadcyla drug for the adjuvant treatment of HER2-positive early breast cancer in patients who are affected by residual invasive disease after undergoing neoadjuvant taxane-trastuzumab-based treatment.

Kadcyla was earlier approved for the treatment of HER2-positive metastatic breast cancer. In March 2017, Roche received FDA approval for its drug named Ocrevus (ocrelizumab) for the treatment of the relapsing form of multiple sclerosis.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/21151

Pharma and Biopharma Companies Investing in R&D

In terms of revenue, the insulin biobetters segment by drug class in the biobetters market is expected to be a prominent segment over the forecast period. By indication, the biobetters market is expected to be dominated by diabetes over the forecast period due to the higher prevalence of the disease.

By route of administration, the subcutaneous segment of the biobetters market is expected to generate significant revenue during the forecast period due to superior drug delivery as compared to intravenous. By distribution channel, the biobetters market is expected to be dominated by the retail pharmacies segment due to higher patient footfall.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/biobetters-market.asp

North America is expected to be a prominent biobetters market through 2029. Biobetters are approved through the biologics approval pathway as new molecules and hence, they have 10 to 12 years of marketing exclusivity in regions such as North America and Europe, which allows pharmaceutical and biopharmaceutical companies to invest in R&D as it provides assurance to the manufacturers.

The manufacturers of originator biologics tend to develop biobetters of their own product, which allows them to maintain/increase their market share due to the superior qualities of biobetters even after the patent expiry of originator biologics. For example, Amgen Inc., a manufacturer of Neupogen, launched Aranesp, a drug used for the treatment of anaemia in patients suffering from chronic kidney diseases as well as chemotherapy/radiation-induced myelosuppression in cancer patients.

Related Reports:

Digital PCR Market - https://www.persistencemarketresearch.com/market-research/digital-pcr-market.asp

Remote Patient Monitoring Device Market - https://www.persistencemarketresearch.com/market-research/remote-patient-monitoring-device-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Biobetters Market to stumble upon digital transformation from 2019-2029, reaching US$ 99,000.0 Mn here

News-ID: 2633269 • Views: 128

More Releases from Persistence Market Research

RFID Tags Market Global Market by Key Regions, Production, Consumption, Revenue, …
The global RFID Tags Market to poised to grow atrociously in the subsequent decade. Artificial Intelligence is expected to have an indelible impact on the day-to-day functionalities. It has already made a beeline to speech and image recognition, smartphone personal assistants, navigation apps, ride-sharing apps, and likewise. This would also help in generating greater employment opportunities. This would be the scene with ICT vertical in the forecast period. The global RFID
The Dressing Vinegar and Condiments Market To Get An Innovative Undertone
Dressing vinegar and condiments are predominantly included in almost every kitchen in the world. Their importance in culinary preparations and food seasonings makes them some of the highly-consumed food ingredients in the world. However, manufacturing of dressing vinegar and condiments has been tainted by emergence of speculated production practices being carried out around the world. Consumers are being conscious regarding health prejudices emanating from contaminated raw materials used in production
Global Consumer Electronic Accessories Market 2022 Trends, Research, Analysis an …
The global Consumer Electronic Accessories Market to poised to grow atrociously in the subsequent decade. Artificial Intelligence is expected to have an indelible impact on the day-to-day functionalities. It has already made a beeline to speech and image recognition, smartphone personal assistants, navigation apps, ride-sharing apps, and likewise. This would also help in generating greater employment opportunities. This would be the scene with ICT vertical in the forecast period. The analysis
Lighting Controllers Market 2022 Global Analysis by Types, Countries and Manufac …
Lighting Controllers Market 2022-2027 New Study Reports "Lighting Controllers Market 2022 Global Opportunities, Strategies, Sizing and Growth, Dynamics, Competitive Landscape, SWOT Analysis and Forecasts 2027" has been Added on PMR. Report Overview The analysis includes forecasted Lighting Controllers Market valuation and growth rate, as per the researchers' review. This Lighting Controllers Market Review provides a summary of current market dynamics, barriers, drivers, and metrics as well as a perspective for important segments. Business

All 5 Releases


More Releases for Biobetters

Global Biobetters Industry Research Report, Growth Trends and Competitive Analys …
This report studies the Biobetters market size by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis. The term biobetter refers to a recombinant protein drug that is in the same class as an existing biopharmaceutical but is not
SMi’s Biosimilars & Biobetters Exclusive Interview with expert speaker Dr Mich …
SMi Reports: An exclusive interview with Dr Michel Mikhail, an independent consultant and chairman of this year’s Biosimilars & Biobetters conference, is now available to download on the event website. SMi Group recently caught up with expert speaker Dr Michel Mikhail, International Expert in Regulatory Affairs and Global Expert in Biosimilars, in the run up to the 9th annual conference on Biosimilars & Biobetters, taking place 26th – 27th September 2018
Registration Opens for the 9th annual Biosimilars and Biobetters 2018 conference
SMi Reports: Registration for SMi’s 9th annual Biosimilars and Biobetters conference has opened and the brochure is available to download SMi Group is proud to announce the return of the 9th annual Biosimilars and Biobetters conference, taking place on the 26th and 27th September 2018 in London, UK. Registration for the event is now open and the newly released brochure is available to download from the event website. This year’s conference
Biobetters Market to Maintain Healthy CAGR in Coming Years
Biobetters is a molecular entities that are similar to existing biologics entities by action, potency and by other factors. The major different is that the biobetters is much more improved from the original biological entities, in many ways such as improved disposition, high efficacy, improved dose to target the problem area. Biobetters are used for various patient section for treating the diseases. The structure of biobetters are very similar original
International Conference On Biobetters and Regulatory Implications
“International conference on Biobetters and Regulatory Implications” will provide a platform to discuss the current vital issues, regulatory issues, market assessment and commercialization and globalization. This interesting event is organized to provide a unique platform for educators and academia. The Conference will bring together industry experts to explore the strategies to gain insight in to new development strategies, different characterization and clinical advancement and successful studies. Conference Series Kemp House,152 City
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperio …
"The Report Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and